112 Poster Presentations

cystis Jirovecii Pneumonia in non-HIV immunosuppressed patients: Acase series

Sourabh Chakraborty, Rajeev Soman, Geethu Joe Juniter Hospital, Pune, Pune, India

Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM

Objective: Increased usage of immunosuppressive medications and lack of guidance about when to initiate primary Pneumocystis Jirovecii Pneumonia (PCP) prophylaxis has led to a rising incidence of PCP in non-HIV immunosuppressed patients. The objective of this case series is to review clinical challenges in diagnosis and management of these patients.

Patients, methods, and results: This is a retrospective case series of all 6 cases which were seen at Jupiter Hospital from January 2020 to October 2021 (Table 1).

Conclusion: The presence of the above-mentioned predisposing factors should raise the suspicion of PCP. Non-invasive nvestigations like serum LDH, BDG, PET CT scan/HRCT scan of chest can help in the diagnosis. This can be confirmed by BAL PCR, which is both, more sensitive and specific than immunofluorescence microscopy. Trimethoprim- sulfamethoxazole (TMP- SMX), the standard treatment, cannot be used in some circumstances and alternate treatment may have to be used.

Guidance about prophylaxis, antimicrobial therapy for PCP, and adjuvant steroid therapy in non-HIV patients is unavailable, which is an unmet clinical need.

First report of Asteroillus tamarii producing influenza associated invasive pulmonary Aspereillosis

Monalisa Sahu², Sourabh Chakraborty¹, Geethu Joe¹, Rahul Doshi¹, Rajeev Soman¹

¹ Jupiter Hospital, Pune, Pune, India

²Yashoda Hospitals, Hyderabad, India

Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM

Objective: Multiple infections can occur after 2009, pandemic influenza, including fungal and bacterial infections, but data from India are limited. To our knowledge, this is the first reported case of influenza-associated mysaive pulmonary aspergillosis (IAPA), caused by Aspergillus tamarii, after infection with pandemic (H1N1) 2009 which was preceded by COVID-19, 20 months before.

Methods and Results: A 33-year-old male, known asthmatic, had been hospitalized elsewhere in August 2020 with COVID-19 pneumonia for 50 days and had been on mechanical ventilation for 37 days. He had no residual respiratory symptoms 3 months after recovery from COVID-19. He was admitted to Jupiter Hospital in April 2022 with fever, cough, and dyspnea for 8 days, which developed after a cold bath in a temple. HRCT (chest) showed ground glass opacities (GGOs), crazy paving, nodules, and traction bronchiectasis. Review of previous HRCT showed that only GGOs were present (Fig. 1).

At admission, the nasopharyngeal swab was positive for pandemic (H1N1) 2009 in the filmarray respiratory panel and no other pathogen was detected. He was treated with oseltamivir. Expectorated sputum examination showed a heavy load of thin septate hyphae, with acute angle branching, resembling Aspergilllus species (Fig. 2). Serum galactomannan was positive (1.8). Based on these features he was diagnosed as a case of probable IAPA and initiated posaconazole (PCZ) treatment. Sputum fungal culture was positive and was identified by MALDI TOF MS as A. tamarii. A. tamarii has been rarely encountered as a human pathogen. Case reports of its involvement in eyelid infection, keratitis, invasive sinonasal infection, and onychomycosis exist. Sensititre MICs were 0.0625 mcg/ml, 0.125 mcg/ml, 0.0625 mcg/ml, and 0.125 mcg/ml. for itraconazole, voriconazole, PCZ, and for isavuconazole (ISVCZ) respectively.

The usually obtained PCZ trough level with standard dose is 1.2 mg/l which generates AUC of 200R. The usually obtained ISVCJ trough level with standard dose is 1.2 mg/l which generates AUC of 100R. The PKPD index, AUC/MIC of 100, is needed with both these azoles for a therapeutic effectR. Therefore, it would be possible to treat this infection with any of these azoles. PCZ was continued in view of the easy availability of therapeutic drug monitoring (TDM) to assure adequate drug expo-

sure, lower cost, and clinical improvement which had already occurred.

Conclusion: An infection due to a rare Aspergillus species needs correct identification, MIC determination, and PKPD consideration for appropriate drug selection and management.

1000000	Manifestations and interval between outer of symptom and diagnosts	Radiology	(UL)	(pg/ml)	PCR (copies/ml)	Treatment	Steroids	Outcome	Secondary prophylaxi
Prednisolone, Rituximab		HRCT: typical	NO	>528	NO	Caspofungin TMP- SMX	High dose needed impossible to taper down Attempt lied to need for ventilator	Severe oral HSV Secondary VAP Klebsiella pneumoniae, Psuedomonas aeruginosa bacteremia Expired	
Prednisolone,	Fever, dyspnosa, desaturation 28 days	HRCT: typical	NO	⊬523	BAL 140052	TMP SAIX		Cured	TMP SMX
Past PCP (was not on primary prophylaxis) CMV	Weight loss 7-8 kgs fever (more towards evening) Desaturation (5 min walk test +) 56 days	PET CT: typical	281	>528	BAL> 112000	Clindamycin Primaquine Caspofungin TMP SMX was avoided due to possibility of renal decompensation & hyperkalemia	increased	Cured	TMP SMX
Azathioprine Recent CMV with ongoing treatment	Fever Weight loss 50kg 75 days	HRCT: typical	357	NO	NO	Clindamycin Primaguine Caspofungin TMP SMX avoided due to concurrent vGCV	Increased	Cured CMV recurred	TMP SMX
Temozolamide Radiotherapy		HRCT: typical	291	266	NO	Clindamycin Primaquine Caspofungin TMP SMX avoided due to neutropenia	increased	Neutropenia recovered & IRIS developed worsening sats & imaging abnormalities	TMP SMX
Prednisolone, Leftunomide	Dry cough Desaturation 21 days	HRCT: atypical for PCP	NO	H523	454864	TMP SAIX	increased	improved (on treatment)	-




Figure 1. PET CT showing FDG uptake & HRCT showing Bilateral GGO with basal sparing




Figure 2. PET CT showing FDG uptake & HRCT showing Bilateral GGO with peripheral sparing